Similar articles

• Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.

  Gillespie JI, Palea S, Guilloteau V, Guerard M, Lluel P, Korstanje C. Gillespie JI, et al. BJU Int. 2012 Jul;110(2 Pt 2):E132-42. doi: 10.1111/j.1464-410X.2012.11240.x. BJU Int. 2012. PMID: 22734512
• Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats.

  Hatanaka T, Ukai M, Watanabe M, Someya A, Ohtake A, Suzuki M, Ueshima K, Sato S, Kaku S. Hatanaka T, et al. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jan;386(1):71-8. doi: 10.1007/s00210-012-0814-3. Epub 2012 Dec 9. Naunyn Schmiedebergs Arch Pharmacol. 2013. PMID: 23224420
• Effects of ritobegron (KUC-7483), a novel β3-adrenoceptor agonist, on both rat bladder function following partial bladder outlet obstruction and on rat salivary secretion: a comparison with the effects of tolterodine.

  Maruyama I, Yonekubo S, Tatemichi S, Maruyama K, Hoyano Y, Yamazaki Y, Kusama H. Maruyama I, et al. J Smooth Muscle Res. 2012;48(5-6):115-24. doi: 10.1540/jsmr.48.115. J Smooth Muscle Res. 2012. PMID: 23538508
• Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data.

  Nilvebrant L, Hallén B, Larsson G. Nilvebrant L, et al. Life Sci. 1997;60(13-14):1129-36. doi: 10.1016/s0024-3205(97)00057-x. Life Sci. 1997. PMID: 9121357 Review.
• Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.

  Tyagi P, Tyagi V. Tyagi P, et al. IDrugs. 2010 Oct;13(10):713-22. IDrugs. 2010. PMID: 20878594 Review.